NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020.
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Biosimilar Pharmaceuticals
/ economics
Chemotherapy-Induced Febrile Neutropenia
/ drug therapy
Drug Approval
Drug Costs
Education, Medical, Continuing
Hematopoietic Cell Growth Factors
/ economics
Humans
Medical Oncology
/ education
Neoplasms
/ blood
Oncologists
/ education
Organizations, Nonprofit
/ standards
Practice Guidelines as Topic
Risk Factors
United States
United States Food and Drug Administration
/ legislation & jurisprudence
Journal
Journal of the National Comprehensive Cancer Network : JNCCN
ISSN: 1540-1413
Titre abrégé: J Natl Compr Canc Netw
Pays: United States
ID NLM: 101162515
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
entrez:
8
1
2020
pubmed:
8
1
2020
medline:
9
2
2021
Statut:
ppublish
Résumé
Management of febrile neutropenia (FN) is an integral part of supportive care for patients undergoing cancer treatment. The NCCN Guidelines for Hematopoietic Growth Factors provide suggestions for appropriate evaluation, risk determination, prophylaxis, and management of FN. These NCCN Guidelines are intended to guide clinicians in the appropriate use of growth factors for select patients undergoing treatment of nonmyeloid malignancies. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines regarding the incorporation of newly FDA-approved granulocyte-colony stimulating factor biosimilars for the prevention and treatment of FN.
Identifiants
pubmed: 31910384
doi: 10.6004/jnccn.2020.0002
pii: jnccnGLINS1801
doi:
pii:
Substances chimiques
Biosimilar Pharmaceuticals
0
Hematopoietic Cell Growth Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM